Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) EBITDA (2019 - 2023)

Historic EBITDA for ADC Therapeutics (ADCT) over the last 5 years, with Q3 2023 value amounting to $2.7 billion.

  • ADC Therapeutics' EBITDA rose 8741535.0% to $2.7 billion in Q3 2023 from the same period last year, while for Sep 2023 it was $2.7 billion, marking a year-over-year increase of 10432.32%. This contributed to the annual value of $4.3 billion for FY2022, which is 217896.54% up from last year.
  • Per ADC Therapeutics' latest filing, its EBITDA stood at $2.7 billion for Q3 2023, which was up 8741535.0% from $2.5 billion recorded in Q2 2023.
  • Over the past 5 years, ADC Therapeutics' EBITDA peaked at $4.3 billion during Q4 2022, and registered a low of -$62.8 billion during Q4 2021.
  • Over the past 5 years, ADC Therapeutics' median EBITDA value was -$35732.0 (recorded in 2019), while the average stood at -$3.2 billion.
  • As far as peak fluctuations go, ADC Therapeutics' EBITDA plummeted by 16102302863.17% in 2021, and later skyrocketed by 8741535.0% in 2023.
  • ADC Therapeutics' EBITDA (Quarter) stood at -$35732.0 in 2019, then soared by 99.85% to -$52.43 in 2020, then plummeted by 119747081612.06% to -$62.8 billion in 2021, then soared by 106.92% to $4.3 billion in 2022, then plummeted by 37.44% to $2.7 billion in 2023.
  • Its last three reported values are $2.7 billion in Q3 2023, $2.5 billion for Q2 2023, and -$51.6 million during Q1 2023.